Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)
Shots:
- The P-III STELLAR-4 study involves assessing of Selonsertib (18mg- 6mg- qd) vs PBO (qd) in patients with compensated cirrhosis (F4) due to NASH for 240 wks.
- The P-III study didn’t meet its 1EPs @48wks.- achieved a ≥ 1-stage improvement in fibrosis (14.4%- 12.5% or 12.8%) and was well-tolerated with safe results
- Selonsertib is qd an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1)- evaluated in P-II ATLAS study in combination with cilofexor (GS-9674) and firsocostat (GS-0976) for advanced fibrosis due to NASH
Ref: Gilead | Image:Gilead
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com